Allen Lutz

Novo Nordisk A/S (NYSE:NVO) said on Monday it has filed a lawsuit against telehealth company Hims & Hers Health Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with compounded semaglutide products for the U.S. market. • Hims & Hers Health stock is at significant support. What...

Shares of Hims & Hers Health Inc (NYSE:HIMS) are under pressure Tuesday, after the company reported downbeat second-quarter revenues. The announcement came amid an exciting earnings season. Here are some key analyst takeaways. BofA Securities analyst Allen Lutz maintained an Underperform...

On July 10, Bank of America Corp (NYSE: BAC) analyst Allen Lutz published an analyst note on Teladoc Health, Inc (NYSE: TDOC). What Happened: The Bank of America analyst had a Neutral rating on Teladoc with a $42 price objective. Lutz’s analysis came after the company...

A brutal 12 months for Teladoc Health Inc (NYSE: TDOC) went from bad to much worse on Thursday when the stock dropped another 43% after the company reported much larger-than-expected losses in the first quarter and slashed its 2022 guidance. On Wednesday, Teladoc reported a whopping EPS loss of $41...

HealthEquity Inc (NASDAQ: HQY) outperformed third-quarter expectations with a 47-cent bottom-line more than double analyst forecasts. Revenue of $157.1 million also beat consensus estimates of $152.4 million, while EBITDA closed the quarter at $56 million against $43 million forecasts....

Health care savings institution HealthEquity, Inc. (NASDAQ: HQY)'s stock has rallied roughly 30 percent since Bank of America Merrill Lynch initiated coverage of the company in May, leading to a downgrade on valuation Thursday. The Analyst BofA's Allen Lutz downgraded HealthEquity from Buy...